Free Trial

BioVie (BIVI) Competitors

BioVie logo
$1.60 +0.08 (+5.26%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.63 +0.03 (+1.87%)
As of 08/22/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BIVI vs. IBIO, CARM, ERNA, GOVX, MTNB, SNPX, TAOX, LGVN, SONN, and IXHL

Should you be buying BioVie stock or one of its competitors? The main competitors of BioVie include iBio (IBIO), Carisma Therapeutics (CARM), Ernexa Therapeutics (ERNA), GeoVax Labs (GOVX), Matinas Biopharma (MTNB), Synaptogenix (SNPX), Synaptogenix (TAOX), Longeveron (LGVN), Sonnet BioTherapeutics (SONN), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry.

BioVie vs. Its Competitors

BioVie (NASDAQ:BIVI) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

BioVie has higher earnings, but lower revenue than iBio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/A-$17.54M-$79.10-0.02
iBio$375K41.46-$24.91MN/AN/A

BioVie has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, iBio has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

iBio's return on equity of -73.15% beat BioVie's return on equity.

Company Net Margins Return on Equity Return on Assets
BioVieN/A -89.02% -75.32%
iBio N/A -73.15%-45.51%

In the previous week, iBio had 4 more articles in the media than BioVie. MarketBeat recorded 4 mentions for iBio and 0 mentions for BioVie. iBio's average media sentiment score of 0.50 beat BioVie's score of 0.00 indicating that iBio is being referred to more favorably in the news media.

Company Overall Sentiment
BioVie Neutral
iBio Neutral

iBio has a consensus price target of $5.00, indicating a potential upside of 532.11%. Given iBio's higher probable upside, analysts clearly believe iBio is more favorable than BioVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioVie
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
iBio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

4.6% of BioVie shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 2.4% of BioVie shares are held by company insiders. Comparatively, 0.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

iBio beats BioVie on 8 of the 13 factors compared between the two stocks.

Get BioVie News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIVI vs. The Competition

MetricBioVieMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.83M$2.54B$5.75B$9.62B
Dividend YieldN/A1.57%4.40%4.10%
P/E Ratio-0.0222.9131.3026.05
Price / SalesN/A554.08432.98193.75
Price / CashN/A180.4637.7358.48
Price / Book0.635.939.536.61
Net Income-$17.54M$31.83M$3.26B$265.65M
7 Day Performance-3.03%1.89%2.13%2.02%
1 Month Performance-80.58%1.33%2.80%-0.31%
1 Year Performance-95.05%8.84%30.68%19.06%

BioVie Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIVI
BioVie
0.3537 of 5 stars
$1.60
+5.3%
N/A-95.2%$2.83MN/A-0.0210Analyst Downgrade
IBIO
iBio
1.8724 of 5 stars
$0.74
+0.2%
$5.00
+573.1%
-60.3%$12.27M$375K0.00100News Coverage
Gap Down
CARM
Carisma Therapeutics
2.9892 of 5 stars
$0.28
-4.5%
$1.93
+590.0%
-80.2%$12.20M$19.63M-0.1820News Coverage
Short Interest ↓
ERNA
Ernexa Therapeutics
0.3855 of 5 stars
$1.61
+1.6%
N/A-94.7%$12.16M$580K-0.1910Short Interest ↑
GOVX
GeoVax Labs
1.8482 of 5 stars
$0.74
-2.6%
$8.88
+1,099.3%
-89.5%$12.09M$3.95M-0.3710Short Interest ↑
Gap Up
MTNB
Matinas Biopharma
0.6933 of 5 stars
$1.71
-27.5%
N/AN/A$12.01MN/A-0.3530High Trading Volume
SNPX
Synaptogenix
N/A$8.40
-8.6%
N/A+72.9%$11.68MN/A-0.834Gap Up
TAOX
Synaptogenix
N/A$8.34
-0.7%
N/AN/A$11.67MN/A-0.414Earnings Report
Gap Up
LGVN
Longeveron
3.5406 of 5 stars
$0.81
+6.4%
$7.25
+796.2%
-69.6%$11.54M$2.39M-0.1320
SONN
Sonnet BioTherapeutics
3.0118 of 5 stars
$3.35
-5.4%
$20.00
+497.0%
-38.1%$11.21M$20K0.0010Gap Down
IXHL
Incannex Healthcare
0.3862 of 5 stars
$0.40
+5.2%
N/A-66.8%$11.19M$10K-0.333News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:BIVI) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners